Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Afivastobart · AB-598

Monoclonal antibody · Inhibitor of CD39 (ENTPD1) · developed by Arcus Biosciences

Phase 1 Most advanced trial
RCUS Developer
1 Registered trials

What is Afivastobart?

Afivastobart is an Fc-silent IgG1 human monoclonal antibody that binds the cell surface ectonucleosidase CD39 (ENTPD1). By blocking CD39, it prevents the breakdown of extracellular ATP to AMP, raising immunogenic ATP and lowering immunosuppressive adenosine in the tumor microenvironment. It is studied in multiple solid tumors, including non-small cell lung cancer, renal cell carcinoma, and triple negative breast cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
AB-598
Drug type
Monoclonal antibody
Targets
CD39 (ENTPD1)
Mechanism
Inhibitor of CD39 (ENTPD1)
Pathways
ATP-to-adenosine conversion, adenosine-mediated immunosuppression, T-cell proliferation, dendritic and myeloid cell stimulation
Therapy area
Oncology
Developer
Arcus Biosciences, Inc. (RCUS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
V58T7C4Y9V

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05891171 Phase 1 Advanced Cancer Active not recruiting RCUS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerAdvanced MalignanciesBladder CancerCervical CancerEsophageal CancerGastric CancerGastroesophageal-junction Cancer (GEJ)Head and Neck Squamous Cell Carcinoma (HNSCC)Non-Small Cell Lung Cancer (NSCLC)Ovarian CancerRenal Cell Carcinoma (RCC)Triple Negative Breast Cancer (TNBC)

Other drugs acting on ENTPD1

More from Arcus Biosciences

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the RCUS page.

Follow RCUS, the company behind Afivastobart

See RCUS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RCUS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.